Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665112 | 0.85 | — | — | |
| SCHEMBL261210 | 0.73 | MT-CO2 (0.46) | MAPTALDH1A1KMT2AMT-CO2POLB | |
| SCHEMBL31473494 | 0.71 | — | — | |
| SCHEMBL13933099 | 0.70 | — | — | |
| SCHEMBL17767271 | 0.68 | MMP8 (0.36) | MAPTKMT2ATLR4 | |
| SCHEMBL10973047 | 0.67 | MAPT (0.33) | MAPTALDH1A1MT-CO2POLB | |
| SCHEMBL124901 | 0.67 | — | — | |
| SCHEMBL8101389 | 0.67 | MAPT (0.55) | MAPTALDH1A1KMT2APOLB | |
| SCHEMBL9609518 | 0.67 | MAPT (0.36) | MAPTALDH1A1KMT2APOLB | |
| SCHEMBL17108508 | 0.65 | MT-CO2 (0.39) | MAPTALDH1A1KMT2AMT-CO2TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046147-B1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2013-05-01 | — | — | EP | claimed |
| US-20090311403-A1 | Method of Using Organic Compounds | GIVAUDAN SA (CH) | 2009-12-17 | — | — | US | claimed |
| CN-101494999-A | Method for using organic compound | GIVAUDAN SA (CH) | 2009-07-29 | — | — | CN | claimed |
| EP-2046147-A1 | METHOD OF USING ORGANIC COMPOUNDS | Givaudan SA (CH) | 2009-04-15 | — | — | EP | claimed |
| WO-2008011742-A1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-31 | — | — | WO | claimed |
| CN-119678921-A | Cyclohexene derivative with attraction effect on carpiotosia borer as well as preparation method and application thereof | 华东理工大学 | 2025-03-25 | — | — | CN | disclosed |
| EP-3088955-B1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHINETSU CHEMICAL CO (JP) | 2020-06-03 | — | — | EP | disclosed |
| US-20170197910-A1 | SUBSTITUTED VINYL AND ALKYNYL CYANOCYCLOALKANOLS AND VINYL AND ALKYNYL CYANOHETEROCYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-07-13 | — | — | US | disclosed |
| US-20170197910-A1 | SUBSTITUTED VINYL AND ALKYNYL CYANOCYCLOALKANOLS AND VINYL AND ALKYNYL CYANOHETEROCYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-07-13 | — | — | US | disclosed |
| US-9505765-B2 | 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment | CONFLUENCE LIFE SCIENCES INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150203499-A1 | 4-ALKOXY/ARALKOXY-5-SUBSTITUTED-PYRROLOPYRIMIDINE COMPOUNDS AS TAK1 INHIBITORS IN DISEASE TREATMENT | ACLARIS THERAPEUTICS, INC. | 2015-07-23 | — | — | US | disclosed |
| US-9000192-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-04-07 | — | — | US | disclosed |
| CN-101494999-A | Method for using organic compound | GIVAUDAN SA (CH) | 2009-07-29 | — | — | CN | disclosed |
| EP-2046147-A1 | METHOD OF USING ORGANIC COMPOUNDS | Givaudan SA (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-20090048248-A1 | Octahydropyrano[3,4-C]Pyrrole Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090048248-A1 | Octahydropyrano[3,4-C]Pyrrole Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-7468437-B2 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2008-12-23 | — | — | US | disclosed |
| WO-2008011742-A1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007075528-A2 | OCTAHYDROPYRANO[3,4-C]PYRROLE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070043015-A1 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203499-A1 | 4-ALKOXY/ARALKOXY-5-SUBSTITUTED-PYRROLOPYRIMIDINE COMPOUNDS AS TAK1 INHIBITORS IN DISEASE TREATMENT | MAP3K6, MAP3K20, MAP3K4 | MAPT 225/4885ALDH1A1 1352/4885KMT2A 1391/4885 |
| US-20090311403-A1 | Method of Using Organic Compounds | MGLL, GK, LIPC | MAPT 2208/4885ALDH1A1 788/4885KMT2A 3062/4885 |
| US-20070043015-A1 | Phenyl pyrrolidine ether tachykinin receptor antagonists | TACR1, NPSR1, TACR2 | MAPT 3243/4885ALDH1A1 1817/4885KMT2A 1026/4885 |
| US-20090048248-A1 | Octahydropyrano[3,4-C]Pyrrole Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | MAPT 3110/4885ALDH1A1 421/4885KMT2A 2532/4885 |
| US-20170197910-A1 | SUBSTITUTED VINYL AND ALKYNYL CYANOCYCLOALKANOLS AND VINYL AND ALKYNYL CYANOHETEROCYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | CBR1, CBR3, VRK1 | MAPT 4876/4885ALDH1A1 1954/4885KMT2A 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.